Abstract
Purpose
The role of 18F-FDG-PET/CT in evaluating gastric MALT lymphoma is still controversial. In the literature the detection rate of 18F-FDG-PET/CT in patients with gastric MALT lymphoma is variable, and the reason for this heterogeneity is not still clear. Our aim was to investigate the particular metabolic behavior of these lymphoma.
Materials and methods
Sixty-nine patients (26 female, 43 male) with histologically confirmed gastric MALT lymphoma who underwent a 18F-FDG-PET/CT for initial staging from two centers were included. The PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value (SUVmax), lesion-to-liver SUVmax ratio, and lesion-to-blood pool SUVmax ratio and compared with Ann Arbor stage, epidemiological (age, sex), histological (presence of gastritis, ulcer, H. pylori infection, plasmacytic differentiation, Ki-67 index), and morphological (tumor size, superficial lesions or mass-forming) characteristics.
Results
Thirty-six patients (52 %) had positive PET/CT (average SUVmax was 9±6.7; lesion-to-liver SUVmax ratio 3.7±2.6, lesion-to-blood pool SUVmax ratio 4.8±3.3) at the corresponding gastric lesion; the remaining 33 were not 18F-FDG-avid. In the univariate analysis, 18F-FDG avidity was significantly associated with morphological features (mass forming p<0.001 and high maximum diameter p<0.001), Ann Arbor stage (p=0.010), and Ki67 index (p<0.001) and not correlated with age, sex, presence of gastritis, ulcer, Helicobacter pylori infection, and plasmacytic differentiation. In the multivariate analysis, the correlations with gross morphological appearance, Ann Arbor stage, and Ki-67 score were confirmed. SUVmax, lesion-to-liver SUVmax ratio, and lesion-to-blood pool SUVmax ratio correlated significantly only with Ki67 index (p=0.047; p=0.012; p=0.042).
Conclusions
18F-FDG avidity was noted in 52 % of gastric MALT lymphoma and this avidity is correlated with gross morphological characteristics, tumor stage, and Ki-67 index. SUVmax, lesion-to-liver SUVmax ratio, and lesion-to-blood pool SUVmax ratio are correlated only with Ki-67 index, and only lesion-to-liver SUVmax ratio was independently associated with Ki-67 score.
Similar content being viewed by others
References
Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;50:1410–6.
Jaffe ES, Harris NL, Stein H, Vardinam JW. Tumours of haematopoietic and lymphoid tissues: world health organization classification of tumours, pathology, and genetics. Lyon: IARC Press; 2001.
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood. 1997;89:3909–18.
Dreyling M, Thieblemont C, Gallamini A, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857–77.
Taal BG, Burgers JM, van Heerde P, Hart AA, Somers R. The clinical spectrum and treatment of primary non-Hodgkin’s lymphoma of the stomach. Ann Oncol. 1993;4:839–46.
Harris NL, Jaffe ES, Diebold J, et al. The world health organization classification of hematological malignancies report of the clinical advisory committee meeting, Arlie house Virginia, November 1997. Mod Pathol. 2000;13:193–207.
Woehrer S, Strubel B, Chott A, Hoffmann M, Raderer M. Transmortation of MALT lymphoma to pure plasma cells histology following treatment with the anti-CD20 antibody rituximab. Leuk Lymphoma. 2005;46:1645–9.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.
Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the international conference on malignant lymphomas imaging working group. J Clin Oncol. 2014;32:3048–58.
Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol. 2007;17:190–7.
Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4:5.
Schwenzer NF, Pfannenberg AC. PET/CT, MR, and PET/MR in lymphoma and melanoma. Semin Nucl Med. 2015;45:322–31.
Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi144–8.
National Comprehensive Cancer Network guidelines on non-Hodgkin’s lymphomas, version 2. 2014. Available at http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.
Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin. 2016;66:152–71.
Treglia G, Zucca E, Sadeghi R, Cavalli F, Giovanella L, Ceriani L. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis. Hematol Oncol. 2015;33:113–24.
Albano D, Giubbini R, Bertagna F. 18F-FDG PET/CT and primary hepatic MALT: a case series. Abdom Radiol (NY). 2016. doi:10.1007/s00261-016-0800-1.
Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18–2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 1999;10:1185–9.
Hoffmann M, Kletter K, Becherer A, Jager U, Chott A, Raderer M. 18FFluorodeoxyglucose positron emission tomography (18F-FDGPET) for staging and follow-up of marginal zone B-cell lymphoma. Oncology. 2003;64:336–40.
Ambrosini V, Rubello D, Castellucci P, et al. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma. Nucl Med Rev Cent East Eur. 2006;9:37–40.
Fu L, Li H, Wang H, Xu B, Fan Y, Tian J. SUVmax/THKmax as a biomarker for distinguishing advanced gastric carcinoma from primary gastric lymphoma. PLoS One. 2012;7, e50914.
Hirose Y, Kaida H, Ishibashi M, et al. Comparison between endoscopic macroscopic classification and F-18 FDG PET findings in gastric mucosa-associated lymphoid tissue lymphoma patients. Clin Nucl Med. 2012;37:152–7.
Yi JH, Kim SJ, Choi JY, Ko YH, Kim BT, Kim WS. 18F-FDG uptake and its clinical relevance in primary gastric lymphoma. Hematol Oncol. 2010;28:57–61.
Radan L, Fischer D, Bar-Shalom R, et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging. 2008;35:1424–30.
Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007;79:205–9.
Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol. 2005;16:473–80.
Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.
Enomoto K, Hamada K, Inohara H, et al. Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings. Ann Nucl Med. 2008;22:261–7.
Alinari L, Castellucci P, Elstrom R, et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma. 2006;47:2096–101.
Hoffmann M, Wöhrer S, Becherer A, et al. 18F-Fluoro-deoxyglucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol. 2006;17:1761–5.
Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluorodeoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107:175–83.
Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003;21:4157–64.
Sharma P, Suman S, Singh H, et al. Primary gastric lymphoma: utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for detecting relapse after treatment. Leuk Lymphoma. 2013;54(5):951–8.
Carrillo-Cruz E, Marin-Oyaga V, de la Cruz Vicente F, et al. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. Hematol Oncol. 2015;33(4):151–8.
Hwang JW, Jee SR, Lee SH, Kim JH, Seol SY, Lee SM. Efficacy of positron emission tomography/computed tomography in gastric mucosa-associated lymphoid tissue lymphoma. Korean J Gastroenterol. 2016;67:183–8.
Park SH, Lee JJ, Kim HO, et al. 18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in 18F-FDG avidity according to site involvement. Leuk Lymphoma. 2015;56(12):3288–94.
Tsai HK, Li S, Ng AK, Silver B, Stevenson MA, Mauch PM. Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphiod tissue lymphoma. Ann Oncol. 2007;18:672–8.
Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867–73.
Koo HR, Parl JS, Kang KW, Han W, Park IA, Moon WK. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. Eur Radiol. 2015;25:3314–21.
Park S, Lee E, Rhee S, et al. Correlation between semi-quantitative 18F-FDG PET/CT parameters and Ki-67 expression in small cell lung cancer. Nucl Med Mol Imaging. 2016;50:24–30.
Nakamura S, Akazawa K, Yao T, Tsuneyoshi M. A clinicopathologic study of 233 cases with special reference to evaluation with the MIB-1 index. Cancer. 1995;76:1313–24.
Watanabe Y, Suefuji H, Hirose Y, et al. 18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential. Int J Hematol. 2013;97:43–9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Albano, D., Bertoli, M., Ferro, P. et al. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. Eur J Nucl Med Mol Imaging 44, 589–597 (2017). https://doi.org/10.1007/s00259-016-3518-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-016-3518-y